[203Pb]eSOMA-01

Radionuclide: Pb-203
Modality: SPECT
Production route: —
Stage: Reported once
Syntheses indexed: 1

Neuroendocrine neoplasms Preclinical only, no clinical indication yet

What it is

Compound class: Octreotate-based somatostatin analogue peptide (SSTR2-targeting)
Target / mechanism: Somatostatin receptor subtype 2 (SSTR2) PMID 37513897
Clinical application: Neuroendocrine tumors (NETs) PMID 37513897
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	≥96%	≥95%	eSOMA-01	37513897 2023 Pharmaceuticals (Basel) [203Pb]PbCl2 (40 MBq) in 0.5 M HCl ... was added to a mixture of DOTAM-TATE or eSOMA-(01-03) (1 nmol), ascorbic acid/gentisic acid (10 μL, 50 mM), sodium acetate (30 μL, 2.5 M), and H2O (final volume of 140 μL). The mixture was incubated for 20 min at rt. - All labeled compounds were obtained with a RCY ≥ 96% and a RCP ≥ 95%.

Need this precursor?We can point you to suppliers for [203Pb]eSOMA-01, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37513897. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to SPECT: Pb-203 is a gamma emitter used only for SPECT imaging. Linked articles: PMID 37513897.